Nederlands tijdschrift voor geneeskunde. Amsterdam 2006-12-30

[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].

J G H van Nes, C Seynaeve, C J H van de Velde, J W R Nortier

Index: Ned. Tijdschr. Geneeskd. 150(52) , 2863-9, (2006)

Full Text: HTML

Abstract

Postmenopausal patients with hormone-sensitive breast cancer may be eligible for adjuvant hormone therapy. - For years, tamoxifen was the treatment of choice. - However, the side effects associated with tamoxifen, such as endometrial cancer and thromboembolic disorders, and the search for more effective agents have led to the introduction of new hormonal therapies. - The results of randomised trials with the third-generation aromatase inhibitors anastrozole, exemestane and letrozole demonstrate improved efficacy compared to tamoxifen. - Using aromatase inhibitors, the disease-free survival is prolonged and recent data from some studies also show a benefit in overall survival. - Aromatase inhibitors are associated with specific side effects consisting of osteoporosis/increased incidence of fractures and myalgia/arthralgia.

Related Compounds

  • Anastrozole
  • Exemestane

Related Articles:

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.

2014-12-01

[Lancet Oncol. 15(13) , 1460-8, (2014)]

NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions.

2014-08-15

[Cancer Res. 74(16) , 4446-57, (2014)]

Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.

2014-01-01

[J. Cancer Res. Clin. Oncol. 140(1) , 159-66, (2014)]

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.

2015-04-01

[Int. J. Oncol. 46(4) , 1481-90, (2015)]

Sex-dependent influence of endogenous estrogen in pulmonary hypertension.

2014-08-15

[Am. J. Respir. Crit. Care Med. 190(4) , 456-67, (2014)]

More Articles...